Senseonics Holdings, Inc.

Equities

SENS

US81727U1051

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 19:56:41 26/06/2024 BST			5-day change	1st Jan Change
0.386 ^USD	+1.58%		-1.95%	-32.92%

06-23	Transcript : Senseonics Holdings, Inc. - Shareholder/Analyst Call
06-21	Senseonics Expects 2024 Net Revenue $22 Million to $24 Million	MT

Senseonics Holdings, Inc. Provides Earnings Guidance for the First Half 2024

May 13, 2024 at 09:13 pm

Senseonics Holdings, Inc. provides earnings guidance for the first half 2024. For the year, company expects first half of 2024 global net revenue to be $10 million, representing growth of approximately 16% compared to the first half of 2023.

Latest news about Senseonics Holdings, Inc.

Transcript : Senseonics Holdings, Inc. - Shareholder/Analyst Call	06-23
Senseonics Expects 2024 Net Revenue $22 Million to $24 Million	06-21	MT
Senseonics Holdings, Inc. Reaffirms Revenue Guidance for the First Half and Provides Revenue Guidance for the Full Year of 2024	06-21	CI
Transcript : Senseonics Holdings, Inc., Q1 2024 Earnings Call, May 13, 2024	05-13
Senseonics Holdings, Inc. Provides Earnings Guidance for the First Half 2024	05-13	CI
Earnings Flash (SENS) SENSEONICS HOLDINGS Posts Q1 Revenue $5.1M, vs. Street Est of $4.6M	05-13	MT
Senseonics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Senseonics Holdings, Inc. and Mercy Collaborate to Improve Diabetes Population Health Management	05-13	CI
Senseonics Partners with Rimidi to Develop Innovative Diabetes Solution	05-09	CI
Senseonics Holdings, Inc. Announces Eversense CGM System Receives iCGM Designation by the U.S. Food and Drug Administration	04-30	CI
Senseonics Holdings, Inc. Announces Board Changes	03-25	CI
Transcript : Senseonics Holdings, Inc., Q4 2023 Earnings Call, Feb 29, 2024	02-29
Senseonics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Senseonics Holdings, Inc. Provides Revenue Guidance for the First Half of 2024	02-29	CI
Earnings Flash (SENS) SENSEONICS HOLDINGS Posts Q4 Revenue $8M, vs. Street Est of $7.6M	02-29	MT
Senseonics Q4 Revenue Guidance Tops Consensus	01-02	MT
Earnings Flash (SENS) SENSEONICS HOLDINGS Reports Q3 Revenue $6.1M, vs. Street Est of $5.5M	11-09	MT
Senseonics Holdings, Inc. Provides Earnings Guidance for the Year 2023	11-09	CI
Transcript : Senseonics Holdings, Inc., Q3 2023 Earnings Call, Nov 09, 2023	11-09
Senseonics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Senseonics Holdings, Inc. Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study	26/09/23	CI
Senseonics Holdings, Inc.(NYSEAM:SENS) dropped from S&P Healthcare Equipment Select Industry Index	18/09/23	CI
Senseonics Holdings, Inc. Enters into $50 Million Loan Facility with Hercules Capital, Inc	11/09/23	CI
Senseonics Holdings, Inc. announced that it expects to receive $50 million in funding	07/09/23	CI
Insider Buy: Senseonics Holdings	31/08/23	MT

Chart Senseonics Holdings, Inc.

Duration

Period

More charts

Company Profile

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems, Eversense, Eversense XL, and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every five minutes to a mobile app on the user's smartphone. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. Its CGM system continually and accurately measures a person's glucose levels for up to six months.

Sector

Medical Equipment, Supplies & Distribution

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Senseonics Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.38 USD

Average target price

1.633 USD

Spread / Average Target

+329.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
SENSEONICS HOLDINGS, INC.	-32.92%	202M
ABBOTT LABORATORIES	-4.60%	184B
MEDTRONIC PLC	-2.77%	103B
BECTON, DICKINSON AND COMPANY	-4.84%	67.59B
CENCORA, INC.	+15.70%	46.93B
DEXCOM, INC.	-8.76%	43.87B
HOYA CORPORATION	+8.28%	41.2B
METTLER-TOLEDO INTERNATIONAL, INC.	+17.11%	30.47B
TERUMO CORPORATION	+13.59%	24.16B
WEST PHARMACEUTICAL SERVICES, INC.	-7.61%	23.57B

Other Medical Equipment, Supplies & Distribution